Optimising musculoskeletal care for patients with haemophilia

European Journal of Haematology

Volumn 95, Issue , 2015, Pages 11-21

  Carcao, Manuel ^a   Hilliard, Pamela ^b   Escobar, Miguel A ^c   Solimeno, Luigi ^d   Mahlangu, Johnny ^e   Santagostino, Elena ^d  

^a HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c UNIVERSITY OF TEXAS   (United States)

^d FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^e UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Bypassing agents; Elective orthopaedic surgery; Haemophilia; Inhibitors; Joint; Multidisciplinary; Musculoskeletal; Recombinant activated factor VII

Indexed keywords

CASE REPORT; CHILD; COMPLICATION; HEMOPHILIA A; HUMAN; JOINT DISEASES; MALE; PATHOPHYSIOLOGY;

CHILD; HEMOPHILIA A; HUMANS; JOINT DISEASES; MALE;

EID: 84952802322     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12581     Document Type: Review

References (64)

1. Morfini M. Articular status of haemophilia patients with inhibitors. Haemophilia 2008;14(Suppl. 6):20-2.
2. van Dijk K, Fischer K, van der Bom JG, Grobbee DE, van den Berg HM. Variability in clinical phenotype of severe haemophilia: the role of the first joint bleed. Haemophilia 2005;11:438-43.
3. Carcao MD, van den Berg HM, Ljung R, Mancuso ME, PedNet and the Rodin Study Group. Correlation between phenotype and genotype in a large unselected cohort of children with severe hemophilia A. Blood 2013;121:3946-52.
4. Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al.Guidelines for the management of hemophilia. Haemophilia 2013;19:e1-47.
5. Mulder K, Llinás A. The target joint. Haemophilia 2004;10(Suppl. 4):152-6.
6. Luck JV Jr, Silva M, Rodriguez-Merchan EC, Ghalambor N, Zahiri CA, Finn RS. Hemophilic arthropathy. J Am Acad Orthop Surg 2004;12:234-45.
7. Roosendaal G, Lafeber FP. Pathogenesis of haemophilic arthropathy. Haemophilia 2006;12(Suppl. 3):117-21.
8. Valentino LA. Blood-induced joint disease: the pathophysiology of hemophilic arthropathy. J Thromb Haemost 2010;8:1895-902.
9. Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med 1994;236:391-9.
10. Fischer K, van Hout BA, van der Bom JG, Grobbee DE, van den Berg HM. Association between joint bleeds and Pettersson scores in severe haemophilia. Acta Radiol 2002;43:528-32.
11. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007;357:535-44.
12. Gilbert MS. Prophylaxis: musculoskeletal evaluation. Semin Hematol 1993;30(Suppl. 2):3-6.
13. Hilliard P, Funk S, Zourikian N, Bergstrom BM, Bradley CS, McLimont M, Manco-Johnson M, Petrini P, van den Berg M, Feldman BM. Hemophilia joint health score reliability study. Haemophilia 2006;12:518-25.
14. Sun J, Hilliard PE, Feldman BM, Zourikian N, Chen L, Blanchette VS, Luke KH, Poon MC. Chinese hemophilia joint health score 2.1 reliability study. Haemophilia 2014;20:435-40.
15. Feldman BM, Funk SM, Bergstrom BM, et al. Validation of a new pediatric joint scoring system from the International Hemophilia Prophylaxis Study Group: validity of the haemophilia joint health score. Arthritis Care Res (Hoboken) 2011;63:223-30.
16. Iorio A, Marchesini E, Marcucci M, Stobart K, Chan AK. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. Cochrane Database Syst Rev 2011;9:CD003429.
17. Gringeri A, Lundin B, von Mackensen S, Mantovani L, Mannucci PM, ESPRIT Study Group. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost 2011;9:700-10.
18. Tagliaferri A, Di Perna C, Rivolta GF. Secondary prophylaxis in adolescent and adult haemophiliacs. Blood Transfus 2008;6(Suppl. 2):s17-20.
19. Wu R, Luke KH, Poon MC, Wu X, Zhang N, Zhao L, Su Y, Zhang J. Low dose secondary prophylaxis reduces joint bleeding in severe and moderate haemophilic children: a pilot study in China. Haemophilia 2011;17:70-4.
20. Coppola A, Tagliaferri A, Di Capua M, Franchini M. Prophylaxis in children with hemophilia: evidence-based achievements, old and new challenges. Semin Thromb Hemost 2012;38:79-94.
21. Teitel JM, Sholzberg M. Current status and future prospects for the prophylactic management of hemophilia patients with inhibitor antibodies. Blood Rev 2013;27:103-9.
22. Lusher JM. Acute hemarthroses: the benefits of early versus late treatment with recombinant activated factor VII. Blood Coagul Fibrinolysis 2000;11(Suppl. 1):S45-9.
23. Santagostino E, Gringeri A, Mannucci PM. Home treatment with recombinant activated factor VII in patients with factor VIII inhibitors: the advantages of early intervention. Br J Haematol 1999;104:22-6.
24. Salaj P, Brabec P, Penka M, Pohlreichova V, Smejkal P, Cetkovsky P, Dusek L, Hedner U. Effect of rFVIIa dose and time to treatment on patients with haemophilia and inhibitors: analysis of HemoRec registry data from the Czech Republic. Haemophilia 2009;15:752-9.
25. Key NS, Aledort LM, Beardsley D, et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost 1998;80:912-8.
26. Santagostino E, Mancuso ME, Rocino A, Mancuso G, Scaraggi F, Mannucci PM. A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors. J Thromb Haemost 2006;4:367-71.
27. Kavakli K, Makris M, Zulfikar B, Erhardtsen E, Abrams ZS, Kenet G, NovoSeven trial (F7HAEM-1510) investigators. Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial. Thromb Haemost 2006;95:600-5.
28. -1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia 2008;14:287-94.
29. ™2 investigators. Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa. J Thromb Haemost 2014;12:1244-53.
30. Abshire T, Kenet G. Safety update on the use of recombinant factor VIIa and the treatment of congenital and acquired deficiency of factor VIII or IX with inhibitors. Haemophilia 2008;14:898-902.
31. Franchini M, Coppola A, Tagliaferri A, Lippi G. FEIBA versus NovoSeven in hemophilia patients with inhibitors. Semin Thromb Hemost 2013;39:772-8.
32. Baxter Healthcare Corporation. FEIBA Prescribing Information 2013. Available at: http://www.baxter.com/downloads/healthcare_professionals/products/feiba_us_pi.pdf (accessed 19 February 2015).
33. Baxter International Inc. FEIBA Summary of Product Characteristics 2013. Available at: http://www.feiba.com/pdf/FEIBA_SPC.pdf (accessed 19 February 2015).
34. Querol F, Pérez-Alenda S, Gallach JE, Devís-Devís J, Valencia-Peris A, González Moreno LM. Haemophilia: exercise and sport. Apunts Med Esport 2011;46:29-39.
35. Rodriguez-Merchan EC, Goddard NJ. The technique of synoviorthesis. Haemophilia 2001;7(Suppl. 2):11-5.
36. Zelada F, de Almeida AM, Pailo AF, Bolliger R, Okazaki E, de Rezende MU. Viscosupplementation in patients with hemophilic arthropathy. Acta Ortop Bras 2013;21:12-7.
37. Carulli C, Matassi F, Civinini R, Morfini M, Tani M, Innocenti M. Intra-articular injections of hyaluronic acid induce positive clinical effects in knees of patients affected by haemophilic arthropathy. Knee 2013;20:36-9.
38. Carulli C, Civinini R, Martini C, Linari S, Morfini M, Tani M, Innocenti M. Viscosupplementation in haemophilic arthropathy: a long-term follow-up study. Haemophilia 2012;18:e210-4.
39. Pérez Bianco R, Ozelo MC, Villaça PR, Solano MH, Jimenez Cruze G, Martinez Murillo C, Garcia Chavez J, Mendoza S, Rodriguez Grecco I, Ruiz-Saez A. Diagnosis and treatment of congenital hemophilia with inhibitors a Latin American perspective. Medicina (B Aires) 2008;68:227-42.
40. Rodriguez-Merchan EC. Musculoskeletal complications of hemophilia. HSS J 2010;6:37-42.
41. Escobar M, Maahs J, Hellman E, et al. Multidisciplinary management of patients with haemophilia with inhibitors undergoing surgery in the United States: perspectives and best practices derived from experienced treatment centres. Haemophilia 2012;18:971-81.
42. Kulkarni R. Comprehensive care of the patient with haemophilia and inhibitors undergoing surgery: practical aspects. Haemophilia 2013;19:2-10.
43. Collins PW, Chalmers E, Hart DP, Liesner R, Rangarajan S, Talks K, Williams M, Hay CR, UK Haemophilia Centre Doctors. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization. Br J Haematol 2013;160:153-70.
44. Giangrande PL, Wilde JT, Madan B, Ludlam CA, Tuddenham EG, Goddard NJ, Dolan G, Ingerslev J. Consensus protocol for the use of recombinant activated factor VII [eptacog alfa (activated); NovoSeven] in elective orthopaedic surgery in haemophilic patients with inhibitors. Haemophilia 2009;15:501-8.
45. Teitel JM, Carcao M, Lillicrap D, Mulder K, Rivard GE, St-Louis J, Smith F, Walker I, Zourikian N. Orthopaedic surgery in haemophilia patients with inhibitors: a practical guide to haemostatic, surgical and rehabilitative care. Haemophilia 2009;15:227-39.
46. Wiedel JW, Stabler SS, Geraghty S, Funk S. Joint Replacement Surgery in Haemophilia. World Federation of Hemophilia. Treatment of Hemophilia Series No. 50, 2010. Available at: http://www1.wfh.org/publication/files/pdf-1210.pdf (accessed 17 September 2014).
47. Ozelo MC. Surgery in patients with hemophilia: is thromboprophylaxis mandatory? Thromb Res 2012;130(Suppl. 1):S23-6.
48. Martinowitz U, Schulman S. Coagulation factor concentrates by continuous infusion. Transfus Med Rev 1997;11:56-63.
49. Bayer Pharma AG. Kogenate Bayer Summary of Product Characteristics 2010. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000275/WC500044445.pdf (accessed 4 August 2014).
50. Hedner U, Glazer S, Pingel K, Alberts KA, Blombäck M, Schulman S, Schulman S, Johnsson H. Successful use of rFVIIa in a patient with hemophilia A subjected to synovectomy. Lancet 1988;2:1193.
51. Shapiro AD, Gilchrist GS, Hoots WK, Cooper HA, Gastineau DA. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost 1998;80:773-8.
52. Ingerslev J, Freidman D, Gastineau D, Gilchrist G, Johnsson H, Lucas G, McPherson J, Preston E, Scheibel E, Shuman M. Major surgery in haemophilic patients with inhibitors using recombinant factor VIIa. Haemostasis 1996;26(Suppl. 1):118-23.
53. Rodriguez-Merchan EC, Wiedel JD, Wallny T, Caviglia H, Hvid I, Berntorp E, Rivard GE, Goddard NJ, Querol F. Elective orthopedic surgery for haemophilia patients with inhibitors: new opportunities. Semin Hematol 2004;1(Suppl. 1):109-16.
54. Mehta S, Nelson CL, Konkle BA, Vannozzi B. Total knee arthroplasty using recombinant factor VII in hemophilia-A patients with inhibitors. A report of three cases. J Bone Joint Surg Am 2004;86-A:2519-21.
55. Goudemand J, Tagariello G, Lopaciuk F. Cases of surgery in high-responder haemophilia patients. Haemophilia 2004;10(Suppl. 2):46-9.
56. Goddard N. Case studies: orthopaedic surgery in adult patients with haemophilia A with inhibitors. Haemophilia 2005;11(Suppl. 1):32-7.
57. Balkan C, Karapinar D, Aydogdu S, Ozcan C, Ay Y, Akin M, Kavakli K. Surgery in patients with haemophilia and high responding inhibitors: Izmir experience. Haemophilia 2010;16:902-9.
58. Rodriguez-Merchan EC, Jimenez-Yuste V, Gomez-Cardero P, Alvarez-Roman M, Martin-Salces M, Rodrigues de la Rua A. Surgery in haemophilia patients with inhibitors, with special emphasis on orthopaedics: Madrid experience. Haemophilia 2010;16:84-8.
59. Boadas A, Fernández-Palazzi F, De Bosch NB, Cedeño M, Ruiz-Sáez A. Elective surgery in patients with congenital coagulopathies and inhibitors: experience of the National Haemophilia Centre of Venezuela. Haemophilia 2011;17:422-7.
60. Caviglia H, Candela M, Galatro G, Neme D, Moretti N, Bianco RP. Elective orthopaedic surgery for haemophilia patients with inhibitors: single centre experience of 40 procedures and review of the literature. Haemophilia 2011;17:910-9.
61. Polyanskaya T, Zorenko V, Karpov E, Sampiev M, Mishin G, Vasiliev D. Experience of recombinant activated factor VII usage during surgery in patients with haemophilia with inhibitors. Haemophilia 2012;18:997-1002.
62. Novo Nordisk AG. NovoSeven Summary of Product Characteristics 2014. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000074/WC500030873.pdf (accessed 4 August 2014).
63. Hoffman M, Dargaud Y. Mechanisms and monitoring of bypassing agent therapy. J Thromb Haemost 2012;10:1478-85.
64. Young G, Sørensen B, Dargaud Y, Negrier C, Brummel-Ziedins K, Key NS. Thrombin generation and whole blood viscoelastic assays in the management of hemophilia: current state of art and future perspectives. Blood 2013;121:1944-50.